Clinical Trial: Plerixafor for Poorly Mobilized Lymphoma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Lymphoma
Study Type: INTERVENTIONAL
Official Title: Efficacy and Safety of Plerixafor in Patients With Poorly Mobilized Lymphoma
Brief Summary:
Autologous hematopoietic stem cell transplantation is one of the effective means of lymphoma treatment, but patients who receive transplantation in the absence of sufficient stem cell numbers have a delay in stem cell engraftment and a markedly increased risk of infection and emergence.Plerixafor injection is a strong and specific antagonist of CXCR4.It can rapidly mobilize stem cells from bone marrow into peripheral blood circulation by blocking the combination of SDF1 and CXCR4.Studies have shown that the…
Read more